Article and Video CATEGORIES

Cancer Journey

Search By

Karen Reckamp, MD, MS, is Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center (COHCCC). She received her medical degree from University of Chicago, and her master’s degree in Clinical Investigation from UCLA. She completed residency training in Internal Medicine at Barnes-Jewish Hospital and a Hematology/Oncology fellowship at the David Geffen School of Medicine at UCLA.

Lung Cancer Video Library - The Role of Angiogenesis in Previously Treated NSCLC
Author
Karen Reckamp, MD, MS, GRACE Faculty

 

TRANSCRIPT

The Role of Angiogenesis in Previously Treated Non-Small Cell Lung Cancer (NSCLC) Presented by Karen Reckamp, MD, MS Co-Director, Lung Cancer and Thoracic Oncology Program Medical Director, Clinical Research Operations City of Hope Comprehensive Cancer Center Duarte, California

 

I’m Karen Reckamp, I’m the medical director of the Thoracic Oncology Program and the medical director of Clinical Research at City of Hope Comprehensive Cancer Center in Duarte, California. The role of angiogenesis in lung cancer is really blood vessels feed the tumor and provide the nutrients that the tumor needs to grow and spread and cause metastases. Anti-angiogenic therapy generally in the form of antibody for non-small cell lung cancer can block that and inhibit blood vessel growth thus stunting tumor growth and the ability to develop metastases. The drug that is approved for second-line therapy with chemotherapy Docetaxel is Ramucirumab. This is an anti-VEGF receptor antibody and it binds to the receptor to block the blood vessel growth and inhibit tumor growth. It does this well in conjunction with chemotherapy. There was a clinical trial evaluating Ramucirumab and Docetaxel versus Docetaxel alone as second-line therapy following progression on initial chemotherapy for metastatic non-small cell lung cancer. This included both patients with non-squamous histology and with squamous histology so all non-small cell lung cancers. Patients had an improvement in time to the tumor growth, in overall survival time, and in the amount of the tumor shrinkage for the combination of Ramucirumab and Docetaxel over Docetaxel alone. There are more side effects with the combination and so more people had fevers and low blood counts, but overall the patients did well with both and had limited number of reasons to discontinue. There were similar numbers of patients who died from the treatment in both arms.


 We would like to thank the following companies for their support of this program

 

                

 

 

                        

 

 
 

 

 


  

Next Previous link

Previous PostNext Post

Related Content

Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.  
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on
Thank you for sharing
By LeviDrake on
Hi bluesun,I don't know of…
By JanineT GRACE … on